Nasus Pharma (NSRX) Cash from Financing Activities (2024)
Nasus Pharma's (NSRX) quarterly Cash from Financing Activities came in at $881000.0 in Q4 2024.
Nasus Pharma (NSRX) Cash from Financing Activities (2024) Analysis & Trends
Nasus Pharma (NSRX) has 1 years of Cash from Financing Activities data on file, last reported at $881000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -3.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -1.48 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 2.34 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -3.66 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Nasus Pharma | 32.04 Mn | 32.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 881,000.00 |
| Dec 31, 2024 | 881,000.00 |